PDS Biotechnology Corp — Director's Dealing 2019

Jan 3, 2019

SEC Form 4/A — Form 4/A

Issuer: Edge Therapeutics, Inc. (EDGE)
CIK: 0001472091
Period of Report: 2018-08-15

Reporting Person: Wyant Alyssa (SVP Regulatory Affairs)

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	10710.18	Indirect

Footnotes

F1: Reflects periodic contributions to the issuer's common stock fund in the issuer's 401(K) Plan as of December 28, 2018. This amendment is being filed to include these shares of the issuer's common stock that were omitted in the prior report.